18 October 2017
News and Views
Links and Services
fiogf49gjkf04The most recent Alimentary Pharmacology & Therapeutics examined relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease.
Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) th
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors